DZ2890A1 - 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number: DZ2890A1
Authority: DZ; Algeria
Prior art keywords: carboxamino; tetrahydroquinoline; substituted; preparation; pharmaceutical compositions
Prior art date: 1998-09-17

Application number

DZ990190A

Other languages

English (en)

Inventor

Michael Paul Deninno

George Tetteh

Magnus Aryitey

Roger Benjamin Ruggeri

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

1999-09-13

Publication date

2003-12-15

1999-09-13 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of DZ2890A1 publication Critical patent/DZ2890A1/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)

DZ990190A 1998-09-17 1999-09-13 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ2890A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10086098P	1998-09-17	1998-09-17

Publications (1)

Publication Number	Publication Date
DZ2890A1 true DZ2890A1 (fr)	2003-12-15

Family

ID=22281914

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990190A DZ2890A1 (fr)	1998-09-17	1999-09-13	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (47)

Country	Link
US (4)	US6197786B1 (fr)
EP (1)	EP1114031B1 (fr)
JP (3)	JP3626685B2 (fr)
KR (1)	KR100428330B1 (fr)
CN (1)	CN1331858C (fr)
AP (1)	AP1346A (fr)
AR (1)	AR021481A1 (fr)
AT (1)	ATE297898T1 (fr)
AU (1)	AU752566B2 (fr)
BG (1)	BG65125B1 (fr)
BR (1)	BR9913810A (fr)
CA (1)	CA2344350C (fr)
CO (1)	CO5370678A1 (fr)
CR (1)	CR6310A (fr)
CU (1)	CU23082A3 (fr)
CZ (1)	CZ2001955A3 (fr)
DE (1)	DE69925845T2 (fr)
DK (1)	DK1114031T3 (fr)
DZ (1)	DZ2890A1 (fr)
EA (1)	EA004674B1 (fr)
EE (1)	EE200100166A (fr)
ES (1)	ES2243069T3 (fr)
GE (1)	GEP20033051B (fr)
GT (1)	GT199900150A (fr)
HK (1)	HK1040243A1 (fr)
HN (1)	HN1999000154A (fr)
HR (1)	HRP20010201A2 (fr)
HU (1)	HUP0103506A3 (fr)
ID (1)	ID28026A (fr)
IL (3)	IL141505A0 (fr)
IS (1)	IS5859A (fr)
MA (1)	MA26688A1 (fr)
MY (1)	MY130670A (fr)
NO (1)	NO318830B1 (fr)
NZ (1)	NZ509840A (fr)
OA (1)	OA11650A (fr)
PA (1)	PA8481401A1 (fr)
PE (1)	PE20001069A1 (fr)
PL (1)	PL347099A1 (fr)
PT (1)	PT1114031E (fr)
SK (1)	SK3542001A3 (fr)
TN (1)	TNSN99171A1 (fr)
TR (1)	TR200100768T2 (fr)
TW (1)	TWI242007B (fr)
UA (1)	UA68390C2 (fr)
WO (1)	WO2000017164A1 (fr)
YU (1)	YU16501A (fr)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7906153B2 (en) *	1998-04-08	2011-03-15	Theta Biomedical Consulting & Development Co., Inc.	Anti-inflammatory compositions for treating multiple sclerosis
US20050220909A1 (en) *	2004-03-30	2005-10-06	Theoharides Theoharis C	Composition for protection against superficial vasodilator flush syndrome
US6984667B2 (en) *	1998-04-08	2006-01-10	Theta Biomedical Consulting And Development Co.	Synergistic proteoglycan compositions for inflammatory conditions
US7799766B2 (en) *	1998-04-08	2010-09-21	Theta Biomedical Consulting & Development Co., Inc.	Composition for treating hormonally-dependent cancers
US20080153761A1 (en) *	1998-04-08	2008-06-26	Theoharides Theoharis C	Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040230559A1 (en) *	1999-08-09	2004-11-18	Mark Newman	Information processing device and information processing method
HN2000000203A (es) *	1999-11-30	2001-06-13	Pfizer Prod Inc	Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) *	1999-11-30	2003-04-30	Pfizer Prod Inc	Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US7115279B2 (en) *	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CN1735416A (zh) *	2000-08-15	2006-02-15	辉瑞产品公司	治疗剂组合
WO2002022585A1 (fr) *	2000-09-14	2002-03-21	Kaken Pharmaceutical Co., Ltd.	Composes de tetrahydroquinoline
ES2256461T3 (es) *	2001-04-30	2006-07-16	Pfizer Products Inc.	Compuestos utiles como intermediarios de derivados de 4-aminoquinolina.
TNSN03139A1 (fr) *	2001-06-21	2005-12-23	Pfizer Prod Inc	Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle
JP4547148B2 (ja)	2001-06-22	2010-09-22	ベンド・リサーチ・インコーポレーテッド	非晶質薬剤の吸着物の医薬組成物
JP2005500313A (ja)	2001-06-22	2005-01-06	ファイザー・プロダクツ・インク	基材中の低可溶性薬物の固体分散体および溶解度向上性ポリマーを含有する医薬品組成物
MXPA03011935A (es) *	2001-06-22	2004-03-26	Pfizer Prod Inc	Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1269994A3 (fr)	2001-06-22	2003-02-12	Pfizer Products Inc.	Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
MXPA03011784A (es)	2001-06-22	2004-04-02	Pfizer Prod Inc	Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
GT200200170A (es)	2001-09-28	2003-05-23		Preparacion de inhibidor de cetp anhidro
WO2003053359A2 (fr)	2001-12-19	2003-07-03	Atherogenics, Inc.	1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
IL162533A0 (en) *	2001-12-19	2005-11-20	Atherogenics Inc	Chalcone derivatives and their use to treat diseases
WO2003063833A1 (fr)	2002-02-01	2003-08-07	Pfizer Products Inc.	Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
AR038375A1 (es)	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
CN1688291A (zh) *	2002-02-01	2005-10-26	辉瑞产品公司	含有固体药物分散体的即刻释放剂型
KR100664822B1 (ko)	2002-02-01	2007-01-04	화이자 프로덕츠 인코포레이티드	변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
PL371416A1 (en) *	2002-02-01	2005-06-13	Pfizer Products Inc.	Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
ES2277142T3 (es)	2002-08-30	2007-07-01	Japan Tobacco Inc.	Compuesto de dibencilamina y su uso medicinal.
PL376156A1 (en) *	2002-10-04	2005-12-27	Millennium Pharmaceuticals, Inc.	Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) *	2002-10-04	2009-07-16	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) *	2002-10-04	2009-03-17	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
CA2500083A1 (fr) *	2002-10-21	2004-04-29	Warner-Lambert Company Llc	Derives de tetrahydroquinoline antagonistes de crth2
WO2004056727A2 (fr) *	2002-12-19	2004-07-08	Atherogenics, Inc.	Procede de fabrication de derives de chalcone
WO2004056359A1 (fr) *	2002-12-20	2004-07-08	Pfizer Products Inc.	Formes posologiques comprenant un inhibiteur de la cetp et un inhibiteur de la hmg-coa reductase
EP1961419B1 (fr) *	2002-12-20	2010-03-24	Pfizer Products Inc.	Formes posologiques comprenant un inhibiteur de CETP et un inhibiteur de HMG-CoA reductase
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2004072042A2 (fr) *	2003-02-12	2004-08-26	Carex S.A.	Modulation de l'activite de recepteurs nucleaires
WO2004072046A2 (fr) *	2003-02-12	2004-08-26	Carex S.A.	Modulation de l'activite des recepteurs nucleaires
ZA200508159B (en) *	2003-03-17	2007-03-28	Japan Tobacco Inc	Pharmaceutical compositions of CETP inhibitors
PT1603553E (pt) *	2003-03-17	2012-02-03	Japan Tobacco Inc	Composições farmacêuticas de inibidores de cetp
AU2004222436A1 (en) *	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
US20040204450A1 (en) *	2003-03-28	2004-10-14	Pfizer Inc	Quinoline and quinoxaline compounds
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CN1812983A (zh) *	2003-05-30	2006-08-02	兰贝克赛实验室有限公司	取代的吡咯衍生物及其作为hmg－co抑制剂的用途
KR20060033033A (ko) *	2003-08-04	2006-04-18	화이자 프로덕츠 인크.	콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출 및ｈｍｇ-ｃｏａ 리덕타제 억제제의 순간 방출을 제공하는제형
CL2004001884A1 (es)	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MXPA06001417A (es)	2003-08-04	2006-05-15	Pfizer Prod Inc	Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
RU2330682C2 (ru)	2003-09-26	2008-08-10	Джапан Тобакко Инк.	Способ ингибирования продуцирования остаточных липопротеинов
EP1670765A2 (fr) *	2003-09-30	2006-06-21	Pfizer Products Inc.	Inhibiteurs de la proteine de transfert d'ester de cholesteryle (cetp) et leurs metabolites
PL1670768T3 (pl) *	2003-10-08	2010-01-29	Lilly Co Eli	Związki i sposoby leczenia dyslipidemii
US7390504B2 (en) *	2003-11-07	2008-06-24	Jj Pharma, Inc.	HDL-boosting combination therapy complexes
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
EA200601785A1 (ru)	2004-03-26	2007-02-27	Эли Лилли Энд Компани	Соединения и способы лечения дислипидемии
US7923043B2 (en) *	2004-03-30	2011-04-12	Theta Biomedical Consulting & Development Co., Inc.	Method for protecting humans against superficial vasodilator flush syndrome
UA90269C2 (ru)	2004-04-02	2010-04-26	Мицубиси Танабе Фарма Корпорейшн	Тетрагидрохинолиновые производные и способ их получения
MY139887A (en)	2004-04-02	2009-11-30	Mitsubishi Tanabe Pharma Corp	Tetrahydronaphthyridine derivatives and a process for preparing the same.
JP2008504266A (ja) *	2004-06-24	2008-02-14	イーライリリーアンドカンパニー	異脂肪血症を治療するための化合物及び方法
WO2006004903A2 (fr) *	2004-06-28	2006-01-12	Atherogenics, Inc.	1,2-bis-(phenyl-substitue)-2-propen-1-ones et des compositions pharmaceutiques en contenant
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006033001A1 (fr) *	2004-09-23	2006-03-30	Pfizer Products Inc.	Composes de quinoline
CA2624601C (fr)	2004-10-06	2018-07-03	The Brigham And Women's Hospital, Inc.	Pertinence de niveaux obtenus de marqueurs d'inflammation generalisee a la suite d'un traitement
KR101021828B1 (ko)	2004-10-27	2011-03-17	다이이찌 산쿄 가부시키가이샤	2 이상의 치환기를 갖는 벤젠 화합물
AU2005308575A1 (en) *	2004-11-23	2006-06-01	Warner-Lambert Company Llc	7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
WO2006069162A1 (fr)	2004-12-20	2006-06-29	Reddy Us Therapeutics, Inc.	Nouveaux composes heterocycliques et leurs compositions pharmaceutiques
EP2548894A1 (fr)	2005-02-03	2013-01-23	Bend Research, Inc.	Compositions pharmaceutiques à éfficacité améliorée
BRPI0608553A2 (pt) *	2005-02-24	2010-01-12	Millennium Pharm Inc	antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
WO2006098394A1 (fr) *	2005-03-14	2006-09-21	Japan Tobacco Inc.	Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
JP4681526B2 (ja) *	2005-09-29	2011-05-11	田辺三菱製薬株式会社	医薬組成物
SG166829A1 (en) *	2005-11-08	2010-12-29	Ranbaxy Lab Ltd	Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
UY30118A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compueto amina trisustituido
UY30117A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compuesto amina trisustituido
WO2008020314A2 (fr) *	2006-03-14	2008-02-21	Ranbaxy Laboratories Limited	Formulations de dosage stabilisantes à base de statine
TW200808731A (en) *	2006-03-30	2008-02-16	Tanabe Seiyaku Co	A process for preparing tetrahydroquinoline derivatives
US20100029716A1 (en) *	2006-04-10	2010-02-04	Concert Pharmaceuticals, Inc.	Novel 1,2,3,4- tetrahydroquinoline derivatives
WO2008010087A2 (fr) *	2006-07-14	2008-01-24	Ranbaxy Laboratories Limited	FORMES POLYMORPHES D'UN INHIBITEUR DE LA HMG-CoA-RÉDUCTASE ET LEURS UTILISATIONS
US7750019B2 (en)	2006-08-11	2010-07-06	Kowa Company, Ltd.	Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
ITMI20062254A1 (it) *	2006-11-24	2008-05-25	Acraf	Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
JP5498168B2 (ja)	2006-12-01	2014-05-21	ブリストル−マイヤーズスクイブカンパニー	アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
TW200901959A (en)	2007-03-09	2009-01-16	Indigene Pharmaceuticals Inc	Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US7790737B2 (en)	2007-03-13	2010-09-07	Kowa Company, Ltd.	Substituted pyrimidine compounds and their utility as CETP inhibitors
CA2681628C (fr)	2007-03-16	2016-10-18	Concert Pharmaceuticals, Inc.	Inhibiteurs de proteine de transfert d'ester de cholesterol
MX2009010962A (es)	2007-04-13	2009-12-16	Kowa Co	Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.
JP4846769B2 (ja) *	2007-07-30	2011-12-28	田辺三菱製薬株式会社	医薬組成物
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
JP5654572B2 (ja)	2009-05-15	2015-01-14	ノバルティスアーゲー	アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体
BRPI1010600A2 (pt)	2009-05-15	2016-03-15	Novartis Ag	aril piridina como inibidores de aldosterona sintase
SG176010A1 (en)	2009-05-28	2011-12-29	Novartis Ag	Substituted aminobutyric derivatives as neprilysin inhibitors
JP5420761B2 (ja)	2009-05-28	2014-02-19	ノバルティスアーゲー	ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
TWI450896B (zh) *	2009-06-30	2014-09-01	Lilly Co Eli	反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
US9050275B2 (en) *	2009-08-03	2015-06-09	Theta Biomedical Consulting & Development Co., Inc.	Methods of screening for and treating autism spectrum disorders and compositions for same
US9176146B2 (en) *	2009-08-03	2015-11-03	Theta Biomedical Consulting & Development Co., Inc.	Methods of treating autism spectrum disorders and compositions for same
ES2663351T3 (es)	2009-11-17	2018-04-12	Novartis Ag	Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en)	2009-11-30	2013-11-05	Novartis Ag	Imidazole derivatives as aldosterone synthase inhibitors
MX2012009149A (es)	2010-02-19	2012-09-28	Boehringer Ingelheim Int	Derivados de piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su preparacion.
CA2799708A1 (fr)	2010-05-21	2011-11-24	Pfizer Inc.	2-phenylbenzoylamides
US8877815B2 (en)	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
EP2668507B1 (fr)	2011-01-26	2017-08-23	INSERM - Institut National de la Santé et de la Recherche Médicale	Méthode d'évaluation du risque d'un sujet de contracter une maladie cardiovasculaire
JP2014506887A (ja)	2011-02-17	2014-03-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	三環式ピリジン誘導体、このような化合物を含有する医薬、それらの使用およびそれらの調製のためのプロセス
CA2828343A1 (fr)	2011-03-04	2012-09-13	The Scripps Research Institute	Peptides de type edn3 et utilisations associees
AR087451A1 (es) *	2011-08-17	2014-03-26	Lilly Co Eli	Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
US9150583B2 (en)	2011-08-17	2015-10-06	Boehringer Ingelheim International Gmbh	Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
WO2013080999A1 (fr)	2011-11-29	2013-06-06	興和株式会社	Agent destiné à inhiber l'expression de l'arnm de npc1l1 et/ou de lipg et agent destiné à prévenir et/ou traiter l'obésité
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
NZ710574A (en)	2013-02-14	2017-11-24	Novartis Ag	Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
SG11201507496UA (en)	2013-04-17	2015-11-27	Pfizer	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
BR112016001376A2 (pt)	2013-07-25	2017-10-24	Novartis Ag	bioconjugados de polipeptídeos de apelin sintéticos
US9266925B2 (en)	2013-07-25	2016-02-23	Novartis Ag	Cyclic polypeptides for the treatment of heart failure
RU2703192C2 (ru)	2014-07-30	2019-10-15	Ф. Хоффманн-Ля Рош Аг	Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
MA40378B1 (fr)	2014-08-12	2022-10-31	Newamsterdam Pharma B V	Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de la tétrahydroquinoléine
EP3186242B1 (fr)	2014-08-29	2021-10-06	Tes Pharma S.r.l.	Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
WO2016055901A1 (fr)	2014-10-08	2016-04-14	Pfizer Inc.	Composés d'amide substitué
CA2972871A1 (fr)	2015-01-23	2016-07-28	Novartis Ag	Conjugues d'acides gras de l'apeline synthetique presentant une demi-vie amelioree
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US11248001B2 (en)	2019-01-18	2022-02-15	Astrazeneca Ab	PCSK9 inhibitors and methods of use thereof
AR127698A1 (es)	2021-11-23	2024-02-21	Novartis Ag	Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
US20240391941A1 (en)	2023-05-24	2024-11-28	Novartis Ag	Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5231402A (en) *	1985-04-02	1993-07-27	Telefunken Systemtechnik Gmbh	Method for detecting and classifying helicopters
ATE147732T1 (de) *	1989-03-08	1997-02-15	Merck Sharp & Dohme	Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten
US5231102A (en)	1989-03-08	1993-07-27	Merck Sharp & Dohme, Ltd.	Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) *	1990-06-18	1994-01-04	E. R. Squibb & Sons, Inc.	Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) *	1990-11-26	1995-03-28	E. R. Squibb & Sons, Inc.	Indane and quinoline derivatives
JPH0676403B2 (ja)	1991-01-18	1994-09-28	エスエス製薬株式会社	新規なベンゾ［５，６シクロヘプタ［１，２−ｂピリジン誘導体及びこれを含有する抗アレルギー剤
US5288725A (en)	1992-10-15	1994-02-22	Merck & Co., Inc.	Pyrroloquinoline Bradykinin antagonist
HRP970330B1 (en)	1996-07-08	2004-06-30	Bayer Ag	Cycloalkano pyridines
DE19627431A1 (de)	1996-07-08	1998-01-15	Bayer Ag	Heterocyclisch kondensierte Pyridine
US6170342B1 (en) *	1997-05-19	2001-01-09	Particle Science	Spiral sampler
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) *	1998-09-17	2000-10-31	Pfizer Inc.	Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU2157400A (en)	1998-12-23	2000-07-31	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
ES2256461T3 (es) *	2001-04-30	2006-07-16	Pfizer Products Inc.	Compuestos utiles como intermediarios de derivados de 4-aminoquinolina.

1999
- 1999-09-07 US US09/391,152 patent/US6197786B1/en not_active Expired - Fee Related
- 1999-09-08 PA PA19998481401A patent/PA8481401A1/es unknown
- 1999-09-09 HN HN1999000154A patent/HN1999000154A/es unknown
- 1999-09-10 KR KR10-2001-7003402A patent/KR100428330B1/ko not_active Expired - Fee Related
- 1999-09-10 AU AU54401/99A patent/AU752566B2/en not_active Ceased
- 1999-09-10 ES ES99940424T patent/ES2243069T3/es not_active Expired - Lifetime
- 1999-09-10 PL PL99347099A patent/PL347099A1/xx not_active Application Discontinuation
- 1999-09-10 AR ARP990104555A patent/AR021481A1/es active IP Right Grant
- 1999-09-10 ID IDW20010622A patent/ID28026A/id unknown
- 1999-09-10 OA OA1200100061A patent/OA11650A/en unknown
- 1999-09-10 SK SK354-2001A patent/SK3542001A3/sk unknown
- 1999-09-10 TR TR2001/00768T patent/TR200100768T2/xx unknown
- 1999-09-10 HK HK02101439.5A patent/HK1040243A1/zh unknown
- 1999-09-10 NZ NZ509840A patent/NZ509840A/xx unknown
- 1999-09-10 JP JP2000574074A patent/JP3626685B2/ja not_active Expired - Fee Related
- 1999-09-10 IL IL14150599A patent/IL141505A0/xx not_active IP Right Cessation
- 1999-09-10 CN CNB998110523A patent/CN1331858C/zh not_active Expired - Fee Related
- 1999-09-10 PT PT99940424T patent/PT1114031E/pt unknown
- 1999-09-10 YU YU16501A patent/YU16501A/sh unknown
- 1999-09-10 GE GEAP19995805A patent/GEP20033051B/en unknown
- 1999-09-10 EE EEP200100166A patent/EE200100166A/xx unknown
- 1999-09-10 HU HU0103506A patent/HUP0103506A3/hu unknown
- 1999-09-10 CA CA002344350A patent/CA2344350C/fr not_active Expired - Fee Related
- 1999-09-10 DK DK99940424T patent/DK1114031T3/da active
- 1999-09-10 AP APAP/P/2001/002101A patent/AP1346A/en active
- 1999-09-10 EP EP99940424A patent/EP1114031B1/fr not_active Expired - Lifetime
- 1999-09-10 CZ CZ2001955A patent/CZ2001955A3/cs unknown
- 1999-09-10 GT GT199900150A patent/GT199900150A/es unknown
- 1999-09-10 DE DE69925845T patent/DE69925845T2/de not_active Expired - Fee Related
- 1999-09-10 WO PCT/IB1999/001532 patent/WO2000017164A1/fr not_active Ceased
- 1999-09-10 MY MYPI99003917A patent/MY130670A/en unknown
- 1999-09-10 TW TW088115687A patent/TWI242007B/zh not_active IP Right Cessation
- 1999-09-10 HR HR20010201A patent/HRP20010201A2/hr not_active Application Discontinuation
- 1999-09-10 EA EA200100202A patent/EA004674B1/ru unknown
- 1999-09-10 AT AT99940424T patent/ATE297898T1/de not_active IP Right Cessation
- 1999-09-10 BR BR9913810-7A patent/BR9913810A/pt not_active Application Discontinuation
- 1999-09-10 CO CO99057642A patent/CO5370678A1/es not_active Application Discontinuation
- 1999-09-10 PE PE1999000921A patent/PE20001069A1/es not_active Application Discontinuation
- 1999-09-13 MA MA25765A patent/MA26688A1/fr unknown
- 1999-09-13 TN TNTNSN99171A patent/TNSN99171A1/fr unknown
- 1999-09-13 DZ DZ990190A patent/DZ2890A1/fr active
- 1999-10-09 UA UA2001031790A patent/UA68390C2/uk unknown
2000
- 2000-09-10 CU CU20010050A patent/CU23082A3/es unknown
- 2000-10-10 US US09/685,380 patent/US6586448B1/en not_active Expired - Fee Related
2001
- 2001-02-14 CR CR6310A patent/CR6310A/es unknown
- 2001-02-19 IL IL141505A patent/IL141505A/en unknown
- 2001-02-23 IS IS5859A patent/IS5859A/is unknown
- 2001-03-16 NO NO20011350A patent/NO318830B1/no unknown
- 2001-04-10 BG BG105428A patent/BG65125B1/bg unknown
2003
- 2003-06-27 US US10/607,640 patent/US6906082B2/en not_active Expired - Fee Related
2004
- 2004-08-18 JP JP2004238309A patent/JP2004339239A/ja active Pending
2005
- 2005-06-13 US US11/152,753 patent/US20050245570A1/en not_active Abandoned
2006
- 2006-01-26 IL IL173393A patent/IL173393A0/en unknown
- 2006-04-12 JP JP2006109338A patent/JP2006188542A/ja not_active Abandoned

Also Published As

Publication number	Publication date
NO20011350L (no)	2001-05-09
JP3626685B2 (ja)	2005-03-09
HUP0103506A2 (hu)	2002-01-28
SK3542001A3 (en)	2002-06-04
NO318830B1 (no)	2005-05-09
MA26688A1 (fr)	2004-12-20
EA004674B1 (ru)	2004-06-24
PE20001069A1 (es)	2000-10-19
BG65125B1 (bg)	2007-03-30
KR20010085813A (ko)	2001-09-07
TNSN99171A1 (fr)	2005-11-10
CN1318058A (zh)	2001-10-17
UA68390C2 (en)	2004-08-16
IS5859A (is)	2001-02-23
AU5440199A (en)	2000-04-10
AP1346A (en)	2004-12-15
CZ2001955A3 (cs)	2001-12-12
EP1114031B1 (fr)	2005-06-15
AR021481A1 (es)	2002-07-24
EE200100166A (et)	2002-06-17
WO2000017164A1 (fr)	2000-03-30
DK1114031T3 (da)	2005-09-12
OA11650A (en)	2004-12-07
JP2002526475A (ja)	2002-08-20
PL347099A1 (en)	2002-03-25
EA200100202A1 (ru)	2001-10-22
NO20011350D0 (no)	2001-03-16
BG105428A (en)	2002-01-31
YU16501A (sh)	2004-05-12
GEP20033051B (en)	2003-08-25
HRP20010201A2 (en)	2002-04-30
CU23082A3 (es)	2005-08-17
ID28026A (id)	2001-05-03
TR200100768T2 (tr)	2001-07-23
MY130670A (en)	2007-07-31
BR9913810A (pt)	2001-06-19
CO5370678A1 (es)	2004-02-27
JP2006188542A (ja)	2006-07-20
HUP0103506A3 (en)	2002-11-28
PA8481401A1 (es)	2002-02-21
ATE297898T1 (de)	2005-07-15
CA2344350C (fr)	2007-01-02
IL141505A (en)	2007-02-11
EP1114031A1 (fr)	2001-07-11
JP2004339239A (ja)	2004-12-02
IL141505A0 (en)	2002-03-10
AU752566B2 (en)	2002-09-19
CA2344350A1 (fr)	2000-03-30
US6586448B1 (en)	2003-07-01
CR6310A (es)	2003-11-25
US20040092550A1 (en)	2004-05-13
US6906082B2 (en)	2005-06-14
PT1114031E (pt)	2005-09-30
DE69925845T2 (de)	2006-05-18
HK1040243A1 (zh)	2002-05-31
US20050245570A1 (en)	2005-11-03
GT199900150A (es)	2001-03-03
KR100428330B1 (ko)	2004-04-28
NZ509840A (en)	2002-11-26
DE69925845D1 (en)	2005-07-21
IL173393A0 (en)	2006-06-11
CN1331858C (zh)	2007-08-15
TWI242007B (en)	2005-10-21
US6197786B1 (en)	2001-03-06
AP2001002101A0 (en)	2001-03-31
ES2243069T3 (es)	2005-11-16
HN1999000154A (es)	2000-01-12

Publication	Publication Date	Title
DZ2889A1 (fr)	2003-12-15	4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2780057B1 (fr)	2002-09-13	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26630A1 (fr)	2004-12-20	4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2745A1 (fr)	2003-09-08	BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26472A1 (fr)	2004-12-20	Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2465A1 (fr)	2003-01-18	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26432A1 (fr)	2004-12-20	Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26433A1 (fr)	2004-12-20	Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2414A1 (fr)	2003-01-04	2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26519A1 (fr)	2004-12-20	Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26490A1 (fr)	2004-12-20	Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2155A1 (fr)	2002-10-26	Aazétidines, procédé pour leur préparation, et co mpositions pharmaceutiques les contenant.
DZ2498A1 (fr)	2003-01-25	Dérivés de quinoléine nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.